2018 Myocardial Ischemia Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Myocardial Ischemia Market

June 2018 | 70 pages | ID: 209E8CE500BEN
VPAResearch

Abstracts

Myocardial ischemia (MI) refers to a heart related condition in which a part of the myocardium lacks adequate supply of oxygen and blood flow. It occurs as a result of blockage in coronary artery, causes chest pain. The primary symptoms include chest pain, angina pectoris, breath shortage, sudden physical exertion and emotional stress. Sustained ischemia can lead to myocardial infarction, leading to heart tissue death.

To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Myocardial Ischemia pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Myocardial Ischemia pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Myocardial Ischemia pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Contents

1 TABLE OF CONTENTS

1.1 List of LIST OF FIGURES
1.2 List of Tables

2 MYOCARDIAL ISCHEMIA PIPELINE ANALYSIS

2.1 Disease and Pipeline Overview
2.2 Myocardial Ischemia Pipeline Snapshot
2.3 Myocardial Ischemia Pipeline by Phase
2.4 Myocardial Ischemia Pipeline by Company
2.5 Myocardial Ischemia Pipeline by Mechanism of Action

3 MYOCARDIAL ISCHEMIA- COMPANY WISE PIPELINE ANALYSIS

Angionetics Inc
Aronora Inc
BioCardia, Inc.
Cellmid Ltd
CohBar Inc
Lixte Biotechnology Holdings, Inc.
NoNO Inc
Pathfinder Cell Therapy Inc

4 MYOCARDIAL ISCHEMIA R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details

5 RECENT DEVELOPMENTS IN MYOCARDIAL ISCHEMIA PIPELINE

6 APPENDIX

6.1 About VPA Research
6.2 Sources and Research Methodology

List Of Figures

LIST OF FIGURES

Figure 1: Myocardial Ischemia Pipeline by Phase, H2- 2018
Figure 2: Myocardial Ischemia Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Myocardial Ischemia Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018

List Of Tables

LIST OF TABLES

Myocardial Ischemia Pipeline by Phase, H2- 2018
Myocardial Ischemia Pipeline by Companies, H2- 2018
Myocardial Ischemia Pipeline by Mechanism of Action, H2- 2018
Table 1: Angionetics Inc Myocardial Ischemia Pipeline Drugs, H2- 2018
Table 2: Aronora Inc Myocardial Ischemia Pipeline Drugs, H2- 2018
Table 3: BioCardia, Inc. Myocardial Ischemia Pipeline Drugs, H2- 2018
Table 4: Cellmid Ltd Myocardial Ischemia Pipeline Drugs, H2- 2018
Table 5: CohBar Inc Myocardial Ischemia Pipeline Drugs, H2- 2018
Table 6: Lixte Biotechnology Holdings, Inc. Myocardial Ischemia Pipeline Drugs, H2- 2018
Table 7: NoNO Inc Myocardial Ischemia Pipeline Drugs, H2- 2018
Table 8: Pathfinder Cell Therapy Inc Myocardial Ischemia Pipeline Drugs, H2- 2018